Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07082439 · ClinicalTrials.gov registry record · Phase 2
Pembrolizumab and Odetiglucan in Liver Predominant Metastatic Colorectal Adenocarcinoma
A Phase 2 study of Colorectal Adenocarcinoma Metastatic in the Liver, sponsored by Abramson Cancer Center at Penn Medicine.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 27
- Enrollment target
- 1
- Study location
NCT07082439 is a Phase 2 study of Colorectal Adenocarcinoma Metastatic in the Liver that is actively recruiting participants, run by Abramson Cancer Center at Penn Medicine. The registered enrollment target is 27 participants. The trial reports 1 study location across 1 state.
The verdict
NCT07082439, a Phase 2 study of Colorectal Adenocarcinoma Metastatic in the Liver, is actively recruiting participants, sponsored by Abramson Cancer Center at Penn Medicine.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 27 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will evaluate the safety and effectiveness of the combination of pembrolizumab and odetiglucan in patients with metastatic colorectal cancer that is predominantly in the liver.
Conditions Studied
Interventions
- DRUG Pembrolizumab
- DRUG Odetiglucan
Study Locations (1)
Pennsylvania
- Abramson Cancer Center at the University of Pennsylvania - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2025-09-10 |
| Est. Completion | 2029-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07082439
The ClinicalTrials.gov registry entry for NCT07082439 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Abramson Cancer Center at Penn Medicine, which has 402 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Colorectal Adenocarcinoma Metastatic in the Liver appearing as the primary indexed condition, and to 2 interventions - of which Pembrolizumab is the first listed.
NCT07082439 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT07082439 about?
NCT07082439 is a clinical study titled "Pembrolizumab and Odetiglucan in Liver Predominant Metastatic Colorectal Adenocarcinoma". This study will evaluate the safety and effectiveness of the combination of pembrolizumab and odetiglucan in patients with metastatic colorectal cancer that is predominantly in the liver.
What is the current status of trial NCT07082439?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 27 participants. The study started on 2025-09-10. Estimated completion is 2029-09.
What conditions does trial NCT07082439 study?
This clinical trial studies the following conditions: Colorectal Adenocarcinoma Metastatic in the Liver.
What interventions are being tested in trial NCT07082439?
The interventions under investigation include: Pembrolizumab (DRUG), Odetiglucan (DRUG).
Who is sponsoring clinical trial NCT07082439?
This trial is sponsored by Abramson Cancer Center at Penn Medicine, which has 402 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07082439 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.